Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03827564 · ClinicalTrials.gov registry record · NA
Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease
A NA study, sponsored by Allergan.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03827564 is a NA study that was terminated before completion, run by Allergan. The registered enrollment target is 14 participants.
The verdict
NCT03827564, a NA study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate goblet cell degranulation following acute use of the Intranasal Tear Neurostimulator in participants with dry eye.
Interventions
- DEVICE Intranasal Tear Neurostimulator (ITN) [TrueTear®]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2020-06-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03827564
The ClinicalTrials.gov registry entry for NCT03827564 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal Tear Neurostimulator (ITN) [TrueTear®] is the first listed.
NCT03827564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03827564 about?
NCT03827564 is a clinical study titled "Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease". The purpose of this study is to evaluate goblet cell degranulation following acute use of the Intranasal Tear Neurostimulator in participants with dry eye.
What is the current status of trial NCT03827564?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2019-06-24. Estimated completion is 2020-06-08.
What interventions are being tested in trial NCT03827564?
The interventions under investigation include: Intranasal Tear Neurostimulator (ITN) [TrueTear®] (DEVICE).
Who is sponsoring clinical trial NCT03827564?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.